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Abstract
Growth of the virulent human malaria parasite Plasmodium falciparum is dependent on an extracellular supply of
pantothenate (vitamin B5) and is susceptible to inhibition by pantothenate analogues that hinder pantothenate utilization.
In this study, on the hunt for pantothenate analogues with increased potency relative to those reported previously, we
screened a series of pantothenamides (amide analogues of pantothenate) against P. falciparum and show for the first time
that analogues of this type possess antiplasmodial activity. Although the active pantothenamides in this series exhibit only
modest potency under standard in vitro culture conditions, we show that the potency of pantothenamides is selectively
enhanced when the parasite culture medium is pre-incubated at 37uC for a prolonged period. We present evidence that this
finding is linked to the presence in Albumax II (a serum-substitute routinely used for in vitro cultivation of P. falciparum) of
pantetheinase activity: the activity of an enzyme that hydrolyzes the pantothenate metabolite pantetheine, for which
pantothenamides also serve as substrates. Pantetheinase activity, and thereby pantothenamide degradation, is reduced
following incubation of Albumax II-containing culture medium for a prolonged period at 37uC, revealing the true, sub-
micromolar potency of pantothenamides. Importantly we show that the potent antiplasmodial effect of pantothenamides is
attenuated with pantothenate, consistent with the compounds inhibiting parasite proliferation specifically by inhibiting
pantothenate and/or CoA utilization. Additionally, we show that the pantothenamides interact with P. falciparum
pantothenate kinase, the first enzyme involved in converting pantothenate to coenzyme A. This is the first demonstration of
on-target antiplasmodial pantothenate analogues with sub-micromolar potency, and highlights the potential of
pantetheinase-resistant pantothenamides as antimalarial agents.
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Introduction
Every day approximately half of the world’s population is at risk
of contracting malaria, a lethal infectious disease estimated to have
claimed 655 000 lives [1] (if not more [2]) in 2010. New
chemotherapeutic agents are desperately needed to combat
malaria as Plasmodium falciparum, the most virulent of the parasites
that cause the disease in humans, has developed resistance to all
antimalarial agents in clinical use [3].
Plasmodium falciparum has an absolute requirement for exogenous
pantothenate (vitamin B5; Figure 1) [4,5,6], a precursor of the
essential enzyme cofactor coenzyme A (CoA). Analogues of
pantothenate that interfere with the utilization of pantothenate
by P. falciparum have been shown to inhibit growth of Plasmodium
parasites in vitro and in vivo [5,7,8], raising interest in pantothenate
utilization as a potential antimalarial drug target, and pantothe-
nate analogues as the chemical entities to strike this target [6,9].
The structure of pantothenol, one antiplasmodial pantothenate
analogue identified previously, is shown in Figure 1.
Pantothenamides, pantothenate analogues in which the car-
boxyl group of pantothenate is replaced with an amide group
(Figure 1), have been shown to possess antibacterial activity in vitro
[10,11,12,13,14]; Escherichia coli and Staphylococcus aureus are among
the bacteria demonstrated to be susceptible to inhibition by these
compounds. Pantothenamides have been shown to serve as
substrates of pantothenate kinase (PanK), the first enzyme in the
CoA biosynthesis pathway, and as a consequence inhibit PanK-
catalysed pantothenate phosphorylation [13,15,16,17,18]. The
resultant 4’-phosphopantothenamides are further metabolized by
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the CoA biosynthesis pathway of bacteria to yield analogues of
CoA [17]. Such CoA analogues have been shown to be
incorporated by, and inhibit the function of, acyl carrier protein
[16,19], a protein involved in fatty acid biosynthesis that requires
the 49-phosphopantetheine moiety of CoA for activation. Whether
the mechanism that ultimately results in bacteriostasis is inhibition
of CoA biosynthesis [20], fatty acid biosynthesis [19] or another
CoA-utilizing process, or a combination of the above, remains to
be resolved.
In this study, the effect of a series of pantothenamides (see
Figure 2) on the growth of erythrocytic stage P. falciparum parasites
was investigated. We show for the first time that under standard
in vitro culture conditions pantothenamides inhibit parasite growth,
albeit with modest potency. Serendipitously, however, we discov-
ered that the antiplasmodial potency of pantothenamides is
enhanced considerably when the parasite culture medium used
for growth assays (which contains the commonly used serum
substitute Albumax II [21] or human serum) is pre-incubated at
37uC for a prolonged period. Consequently, sub-micromolar
concentrations of pantothenamides that have no effect in freshly
prepared medium inhibit parasite growth effectively in the pre-
incubated medium. We present evidence that links this finding to
the presence in parasite culture medium of pantetheinase activity,
the activity of an enzyme that catalyzes the hydrolysis of
pantetheine (Figure 1) to pantothenate and cysteamine. In
animals, pantetheinase activity is typically linked with the Vanin
proteins [22], soluble or membrane bound proteins that belong to
the nitrilase superfamily, the members of which share an invariant
Glu-Lys-Cys catalytic triad [23]. We show, using an in vitro
primary amine detection assay, that a pantothenamide selected
from the series tested here is hydrolyzed in the presence of
Albumax II, demonstrating Albumax II to be a source of
pantetheinase activity. Furthermore, we show that recombinant
human pantetheinase (Vanin-1) reduces the antiplasmodial
potency of the pantothenamide in the pre-incubated medium
in vitro, and, that the attenuating effect of the pantetheinase is
alleviated by incubation of the pantetheinase-supplemented
medium at 37uC. Together these data are consistent with
pantetheinase-mediated pantothenamide degradation occurring
in medium freshly supplemented with Albumax II or serum under
in vitro culture conditions, lowering the effective pantothenamide
concentration, and thereby masking the sub-micromolar anti-
plasmodial potency of pantothenamides.
Importantly, we demonstrate that the potent antiplasmodial
effect of the pantothenamides in the medium pre-incubated at
37uC is alleviated with pantothenate, and therefore results
specifically from inhibition of pantothenate and/or CoA utiliza-
tion. We also show that all of the pantothenamides in this series
inhibit P. falciparum PanK-catalysed pantothenate phosphorylation
(and hence serve as substrates or inhibitors of P. falciparum PanK).
The data presented here provide additional validation of
pantothenate and CoA utilization as potential antiplasmodial
drug targets.
Materials and Methods
Reagents
The pantothenamides tested were synthesized and purified as
described previously [18]. Each pantothenamide was dissolved in
dimethyl sulfoxide (DMSO) to a final concentration of 400 mM
before being diluted in the solution pertinent to the experiment.
For in vitro growth assays, the concentration of DMSO introduced
into cultures never exceeded 0.05% (v/v), in phosphorylation
assays the DMSO concentration present was 0.025% (v/v), and in
fluorescamine assays the concentration of DMSO never exceeded
0.15% (v/v). Albumax II was purchased from Life Technologies
(Mulgrave, Victoria, Australia), dissolved to a concentration of
20% (w/v) in water, filter sterilized and stored frozen (220uC).
SYBR Safe DNA gel stain (10 0006 stock concentration) was also
from Life Technologies. Recombinant human pantetheinase
(Vanin-1) was purchased from Novoprotein Scientific Inc. (Short
Hills, New Jersey, USA) and was reconstituted to a concentration
of 200 mg/mL in sterile phosphate-buffered saline and stored at
220uC for no longer than 3 weeks before use. [14C]Pantothenate
(55 mCi/mmol) was purchased from American Radiolabelled
Chemicals, Inc., and pantothenol and fluorescamine were from
Sigma-Aldrich.
Cell Culture
Erythrocytic stage P. falciparum parasites (strain 3D7) were
maintained within human erythrocytes in continuous culture
essentially as described previously [24,25]. P. falciparum-infected
erythrocytes were routinely cultured in RPMI 1640 medium
supplemented with 25 mM HEPES, 20 mM D-glucose, 200 mM
hypoxanthine, 24 mg/L gentamycin and Albumax II (0.6%, w/v),
which, hereafter is referred to as Albumax-complete RPMI. For
several days prior to carrying out the assays testing the effect of
compounds on the growth of P. falciparum in medium supplement-
ed with human serum (instead of Albumax II), the parasites were
cultured in the same medium mentioned above, except that
human serum (10%, v/v, pooled from different blood donors) was
used rather than Albumax II. This medium is hereafter referred to
as human serum-complete RPMI.
In vitro Growth Assays
The in vitro antiplasmodial activity of test compounds was
determined using the malaria SYBR Green I-based fluorescence
assay described by Smilkstein et al. [26], with minor modifications.
Briefly, P. falciparum-infected erythrocytes were incubated in
culture medium containing two-fold dilutions of the test
compounds in 96-well microtiter plates. Assays were initiated
Figure 1. Chemical structures of pantothenate and related
compounds. The hydroxy analogue of pantothenate, pantothenol,
inhibits growth of P. falciparum in vitro and in vivo. Amide analogues of
pantothenate, pantothenamides (for which the core structure is
shown), possess antibacterial activity in vitro. Pantetheine, a naturally
occurring pantothenate derivative, is hydrolyzed to pantothenate (and
cysteamine) by the enzyme pantetheinase.
doi:10.1371/journal.pone.0054974.g001
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Figure 2. Effect of pantothenamides on proliferation of P. falciparum and P. falciparum lysate-catalysed [14C]pantothenate
phosphorylation. The 50% inhibitory concentrations (IC50 values) measured against P. falciparum parasites cultured (for 96 h) in Albumax-complete
RPMI containing 1 mM pantothenate, as determined using the SYBR Green I-based growth assay are shown. Assays were performed using Albumax-
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with ring-stage P. falciparum-infected erythrocytes at a hematocrit
and parasitemia of 1%. Wells containing infected erythrocytes in
the presence of chloroquine (0.25–2 mM) served as zero growth
controls and wells containing infected erythrocytes in the absence
of chloroquine or test compounds served as 100% parasite growth
controls. Plates were incubated at 37uC under an atmosphere of
96% nitrogen, 3% carbon dioxide and 1% oxygen for 96 h, before
100 mL from each well was mixed with 100 mL of SYBR Safe
DNA gel stain (0.2 mL/mL) in 20 mM Tris, pH 7.5, 5 mM
ethylenediaminetetraacetic acid (EDTA), 0.008% (w/v) saponin,
0.08% (v/v) Triton X-100, in a second 96-well microtitre plate.
Fluorescence was measured using a FLUOstar OPTIMA multi-
detection microplate reader from BMG LABTECH with excita-
tion and emission wavelengths of 490 and 520 nm, respectively.
The 50% inhibitory concentration (IC50) of each test compound
under each test condition was calculated by fitting the data to a
sigmoidal curve (typically y= a/(1+ (x/x0)b) using nonlinear least
squares regression (SigmaPlot, Systat Software) and averaging the
IC50 estimates from independent experiments.
Preparation of Culture Medium for in vitro Growth
Assays
The antiplasmodial activity of test compounds was assessed in
media that had been subjected to different pre-incubations.
‘‘Fresh’’ medium refers to medium that was stored for a maximum
of 48 h at 4uC, and incubated at 37uC for a maximum of 1 h,
prior to use. ‘‘Aged’’ medium refers to medium that was stored for
a minimum of one week at 4uC and incubated intermittently at
37uC, or medium incubated continuously at 37uC for 40 h soon
after preparation. As indicated at the relevant positions within the
‘‘Results’’ section, for some experiments the fresh medium used
was, more specifically, medium used immediately following
preparation, and the aged medium used was, more specifically,
medium that was incubated at 37uC for 40 h immediately prior to
use.
[14C]Pantothenate Phosphorylation Assays
To assess the effect of the pantothenamides on pantothenate
phosphorylation by P. falciparum PanK, the phosphorylation of
[14C]pantothenate by P. falciparum lysates was measured in the
presence and absence of a single concentration of each
pantothenamide. P. falciparum lysate was prepared from trophozo-
ite stage parasites ‘‘isolated’’ from their host erythrocyte by
treatment with 0.05% (w/v) saponin (essentially as described by
Saliba et al. [27]), and washed (five times) in HEPES-buffered
saline (125 mM NaCl, 5 mM KCl, 20 mM D-glucose, 25 mM
HEPES, 1 mM MgCl2, pH 7.1). Lysates were prepared as
described by van Schalkwyk et al. [28], except that 10 mM
potassium phosphate, pH 7.4 (rather than 10 mM Tris, pH 7.4),
was used to lyse the cells. Aliquots of lysate were stored at 220uC.
The concentration of cell lysates was determined from cell counts
made using an improved Neubauer hemocytometer.
[14C]Pantothenate phosphorylation was assayed using the
Somogyi reagent [29] essentially as described by Saliba et al.
[27], except that pantothenate phosphorylation was terminated by
heat denaturation (rather than acid denaturation) of the protein in
reaction aliquots. Briefly, P. falciparum lysate was added to solutions
(at 37uC) of 50 mM Tris, 5 mM ATP, 5 mM MgCl2, at pH 7.4,
containing [14C]pantothenate (at a final concentration of
0.01 mCi/mL, or 0.2 mM), and a pantothenamide (at a final
concentration of 100 mM) or an equivalent volume of solvent.
Typically, lysate prepared from 5.4–6.56107 parasites was present
in each mL of reaction solution. Zero phosphorylation control
reactions were prepared by adding a corresponding volume of
10 mM potassium phosphate instead of parasite lysate. Following
a ten minute incubation at 37uC (a period during which
pantothenate phosphorylation increased linearly with time in the
absence of inhibitors) 200 mL aliquots of the [14C]pantothenate
phosphorylation reactions were transferred in duplicate to
microcentrifuge tubes, and immediately incubated at 95uC for
10 min to terminate phosphorylation. Terminated reaction
samples were centrifuged at 15 8006g for 10 min to pellet the
denatured protein, before two aliquots of each supernatant
(typically 80 mL) were transferred to new microcentrifuge tubes.
To one aliquot, 500 mL Somogyi reagent was added, and to the
other, 500 mL water was added. The samples were processed for
determination of phosphorylated [14C]pantothenate as described
previously [27].
In vitro Fluorescamine-based Assay
Hydrolysis of compound 12 to pantothenate and isobutylamine
was measured using a modification of a fluorescence-based assay
described previously for the measurement of N-acetyl-1-D-myo-
inosityl-2-amino-2-deoxy-a-D-glucopyranoside deacetylase activi-
ty [30,31]. The assay utilizes fluorescamine (4-phenylspiro-[furan-
2(3H),1-phthalan]-3,39-dione; a non-fluorescent molecule that
reacts with primary amines to form a fluorescent product [32])
for the detection of primary amines. Briefly, recombinant human
pantetheinase (at a final concentration of 100 ng/mL), Albumax II
(at a final concentration 0.6%, w/v), or an equivalent volume of
water, was added to solutions (at 37uC) of 100 mM potassium
phosphate, pH 7.5, 0.5 mM dithiothreitol, 0.01% (w/v) bovine
serum albumin, 0.1% (v/v) DMSO, with or without pantothena-
mide (at a final concentration of 200 mM). At the appropriate time
points, aliquots (30 mL) of the reaction mixtures were removed in
duplicate and mixed with 10 mL 20% (v/v) trichloroacetic acid to
terminate the reaction. Following removal of the precipitated
protein by centrifugation (14 0006g, 15 min), 25 mL of each
supernatant was transferred to the wells of a black 96-well
microtitre plate and 75 mL 1 M borate (pH 9.0) followed by 30 mL
10 mM fluorescamine was added to the wells. The plate was then
complete RPMI prepared within 48 h of the assay, stored at 4uC, and incubated at 37uC for a maximum of 1 h (fresh) or Albumax-complete RPMI
incubated continuously at 37uC for 40 h immediately after preparation (aged). The IC50 values shown for parasites cultured in fresh Albumax-
complete RPMI are averages from between two and eight independent experiments each performed in duplicate or triplicate. Where the IC50 values
determined were below 200 mM, they are presented as the mean 6 SEM from between three and eight independent experiments. The IC50 values
shown for parasites cultures in aged medium are averages from between two and three independent experiments each performed in triplicate.
Where the IC50 values determined were below 200 mM, they are presented as the mean 6 range/2 or SEM as appropriate. The percentage inhibition
of [14C]pantothenate phosphorylation by PanK in P. falciparum lysate caused by pantothenamides (when tested at a concentration of 100 mM) in the
presence of 0.2 mM pantothenate are also shown. The percentage inhibition was calculated from the measured amounts of [14C]pantothenate
phosphorylated during a 10 min incubation in the presence of pantothenamide and in the presence, instead, of the corresponding concentration of
DMSO only. Data are averages 6 range/2 from two independent experiments, each performed in duplicate. A value of 100 indicates complete
inhibition of [14C]pantothenate phosphorylation was observed in both independent experiments. The amount of [14C]pantothenate phosphorylated
by P. falciparum lysate was significantly lower in the presence of all pantothenamides (P,0.0001, ANOVA).
doi:10.1371/journal.pone.0054974.g002
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incubated at 37uC for 10 min before fluorescence was measured
using a FLUOstar OPTIMA multidetection microplate reader
from BMG LABTECH with excitation and emission wavelengths
of 390 and 485 nm, respectively. The fluorescence detected was
converted to the corresponding isobutylamine concentration using
an isobutylamine standard curve. In each experiment, the
isobutylamine standard curve was generated from aliquots
(30 mL) of isobutylamine solutions (0.02–200 mM) processed in
parallel with the reaction aliquots as described above.
Statistical Analysis
To test for a statistically significant difference between the
means of two groups, two-tailed student t tests were performed. To
test for statistically significant differences between the means of
more than two groups, one-way analysis of variance (ANOVA)
was performed. Pairwise comparisons were made post-hoc with
Tukey’s multiple comparisons test (when comparing all means) or
Dunnett’s multiple comparisons test (when comparing all means
with a control mean). P values reported are multiplicity adjusted.
ANOVA was performed using GraphPad 6 (GraphPad Software,
Inc).
Results
Antiplasmodial Activity of Pantothenamides under
Standard in vitro Culture Conditions
A series of 22 previously published [18] pantothenamides was
tested in vitro for antiplasmodial activity against erythrocytic stage
P. falciparum parasites (strain 3D7) in 96 h growth assays initiated
with parasites predominantly in the ring stage. The series of
pantothenamides (see Figure 2 for structures) was composed of 21
secondary amides of pantothenate, each with a different amide
substituent, as well as a lone tertiary amide. The series included
the prototypical pantothenamides N5-Pan and N7-Pan (com-
pounds 1 and 2, respectively). All of the pantothenamides tested
were stereochemically pure, with R-configuration at the chiral
carbon of the 2,4-dihydroxy-3,3-dimethylbutanamide moiety. As
shown in Figure 2, when tested in ‘‘fresh’’ Albumax-complete
RPMI (Albumax-complete RPMI stored at 4uC for a maximum of
48 h, and incubated at 37uC for a maximum of 1 h, prior to use),
ten of the 22 pantothenamides inhibited proliferation of P.
falciparum parasites with IC50 values below 200 mM. With the
exception of compound 2 (N7-Pan; the pantothenamide with the
longest linear alkyl chain), the pantothenamides with simple alkyl
(linear or branched) or alkenyl amide substituents were among the
ten active pantothenamides. Compound 3 (with a phenethyl
substituent) was the only pantothenamide containing a carbocycle
with an IC50 value below 200 mM.
The potency of pantothenamides with acyclic heteroatom-
containing substituents varied. Three pantothenamides with linear
thioether substituents were tested for antiplasmodial activity;
compounds 17 and 18 were among the most active of the series,
while compound 14 had little effect even at a concentration of
200 mM. Compound 17 was also significantly more active than
N5-Pan, the corresponding alkyl pantothenamide (P = 0.02,
ANOVA). Among the four pantothenamides with linear ether
substituents, compound 19 was the most active (P,0.0001,
ANOVA), compounds 21 and 22 were also active, while
compound 15 lacked antiplasmodial activity at the concentrations
tested. The less polar thioether pantothenamides 17 and 18 were
significantly more active (P,0.003, ANOVA) than the corre-
sponding ether pantothenamides 22 and 21, respectively. Com-
pounds 16 and 20 (both with terminal hydroxyl groups in the
substituent) were without effect even at the highest concentration
tested.
Albumax II-complete RPMI contains 1 mM pantothenate, a
concentration close to the normal whole blood pantothenate
concentration [33]. When the ten pantothenamides with IC50
values below 200 mM were tested against P. falciparum parasites in
fresh Albumax-complete RPMI to which 100 mM pantothenate
was added, the IC50 values measured were between 160.1
(compound 13; mean 6 range/2) and 1.760.4 (compound 19;
mean 6 range/2) times higher than those measured against
parasites in Albumax-complete RPMI containing 1 mM pantothe-
nate. The minor attenuating effect (or lack of an effect) of
pantothenate supplementation on the antiplasmodial activity of
the pantothenamides, contrasts with the dramatic attenuating
effect of pantothenate on the antiplasmodial activity of previously
reported antiplasmodial pantothenate analogues such as pantothe-
nol and CJ-15,801 [5,7,8].
Antiplasmodial Activity in Albumax-complete Medium
Pre-incubated at 37uC for a Prolonged Period
During the course of screening pantothenamides for antiplas-
modial activity, it was serendipitously discovered that a prolonged
37uC pre-incubation of the Albumax-complete RPMI used for a
growth assay has a dramatic effect on the antiplasmodial activity of
pantothenamides. As shown in Figure 2, nine of the ten
pantothenamides that inhibit growth of P. falciparum with IC50
values below 200 mM in fresh Albumax-complete RPMI were
found to be more potent in Albumax-complete RPMI incubated at
37uC for 40 h prior to use (‘‘aged’’ Albumax-complete RPMI)
than in fresh Albumax-complete RPMI. When tested in aged
medium, the IC50 values determined for these nine compounds
were between one and three orders of magnitude lower than the
IC50 values determined when the pantothenamides were tested in
fresh medium. Additionally, four of the 12 pantothenamides that
did not inhibit growth of P. falciparum with IC50 values below
200 mM in fresh Albumax-complete RPMI (compounds 2, 9, 16
and 20) did so in aged Albumax-complete RPMI. The effect of
increasing concentrations of three selected pantothenamides
(compounds 3, 12, and 19) on the growth of P. falciparum in fresh
and aged Albumax-complete RPMI is shown in Figure 3A–C. The
activity of pantothenol was, by contrast with the activity of many
of the pantothenamides, comparable in aged and fresh medium
(P= 0.32, unpaired t test; Figure 3D). Hence, the potency of
pantothenamides is selectively enhanced in aged medium.
Among the most potent pantothenamides in aged medium was
the phenethyl substituted pantothenamide, compound 3
(IC50 = 2062 nM; mean 6 SEM; n= 3). One other carbocycle-
bearing pantothenamide (compound 9; a pantothenamide with a
methoxy-substituted benzyl substituent) was also observed to
inhibit parasite growth in aged medium with an IC50 value below
200 mM, but was significantly less potent (P = 0.0009, ANOVA).
When tested in aged medium, an IC50 value below 200 mM was
measured for compound 2 (N7-Pan), however the pantothenamide
remained less active than the pantothenamides with shorter alkyl
amide substituents (compounds 1, 11 and 12). As observed when
the compounds were tested in fresh medium, in aged medium: (i)
compounds 17 and 18 (two thioether substituted pantothena-
mides) were among the most potent pantothenamides, and the
pantothenamide with the shorter thioether substituent lacked
appreciable activity even at 200 mM; and (ii) the activity of the
pantothenamides with ether substituents increased with increasing
chain length, with compound 19 being among the most potent
pantothenamides. Compounds 16 and 20 (both with terminal
hydroxyl groups in the substituent) demonstrated an inhibitory
Pantothenamides Are Potent Antiplasmodial Agents
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effect in aged medium, however, they remained among the least
potent pantothenamides.
Not only did the potency of pantothenamides in fresh and aged
Albumax-complete RPMI differ, the effect of pantothenate
supplementation on pantothenamide potency differed depending
on whether the compounds were tested in fresh or aged medium;
the effect of supplementation with 100 mM pantothenate was
greater when compounds were tested in aged medium than in
fresh. For example, as shown in Figure 4 (closed bars), the IC50
values determined for compounds 12 and 19 against parasites
cultured in aged Albumax-complete medium supplemented with
100 mM pantothenate were 2161 (mean 6 SEM; n= 3) and
2461 (mean 6 range/2; n= 2) times higher, respectively, than the
corresponding IC50 values against parasites cultured in aged
Albumax-complete RPMI containing 1 mM pantothenate; by
comparison, the IC50 values determined for compounds 12 and
Figure 3. Antiplasmodial effect of pantothenamides and pantothenol in fresh and aged Albumax-complete RPMI. The concentration-
response curves show the effect of increasing concentrations of compound 3 (A), compound 12 (B), compound 19 (C), and pantothenol (D) on
proliferation of P. falciparum parasites cultured (for 96 h) in Albumax-complete RPMI containing 1 mM pantothenate, as measured using the SYBR
Green I-based growth assay. Assays were performed using Albumax-complete RPMI stored for a maximum of 48 h at 4uC, and incubated at 37uC for a
maximum of 1 h (fresh; open circles) or Albumax-complete RPMI incubated continuously at 37uC for 40 h immediately after preparation (aged; closed
circles). The data obtained with parasites cultured in fresh Albumax-complete RPMI are from between three and eight independent experiments
performed in duplicate or triplicate and error bars represent SEM. The data obtained with parasites cultured in aged Albumax-complete RPMI are
from between two and three independent experiments performed in duplicate or triplicate and error bars represent range/2 or SEM. For clarity, in D,
the concentration-response curves represented by the closed circles are shown with negative error bars only, and the concentration-response curves
represented by the open circles are shown with positive error bars only. Where not shown, error bars are smaller than the symbol.
doi:10.1371/journal.pone.0054974.g003
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19 against parasites cultured in fresh Albumax-complete RPMI
supplemented with 100 mM pantothenate were only 1.360.2 and
1.760.4 (mean 6 range/2; n= 2) times higher, respectively, than
the corresponding IC50 values against parasites cultured in fresh
Albumax-complete RPMI containing 1 mM pantothenate
(Figure 4, open bars). These data are consistent with the inhibition
of growth in aged medium resulting from inhibition of pantothe-
nate and/or CoA utilization. Pantothenate was found to
antagonize the antiplasmodial activity of pantothenol effectively
in both fresh and aged medium (Figure 4). Taken together, these
data are consistent with (i) the pre-incubation of Albumax-
complete RPMI at 37uC effecting a change in the medium that
specifically and reproducibly enhances the antiplasmodial activity
of pantothenamides; and (ii) pantothenamides acting via an effect
on pantothenate and/or CoA utilization under these conditions.
Inhibition of Pantothenate Phosphorylation
To explore the mechanism of action of pantothenamides, we
investigated whether, like antiplasmodial pantothenate analogues
reported previously [5,7,8], pantothenamides inhibit P. falciparum
PanK-catalyzed pantothenate phosphorylation. As shown in
Figure 2, in the presence of each pantothenamide, the amount
of [14C]pantothenate phosphorylated by PanK present in P.
falciparum lysate during a 10 min period (in which pantothenate
phosphorylation increased linearly with time under control
conditions) was significantly reduced relative to the amount
phosphorylated in the absence of pantothenamides (P,0.0001,
ANOVA). At the pantothenamide concentration tested (100 mM,
a concentration 500-fold higher than the concentration of
pantothenate present in the assay), each of the pantothenamides
inhibited [14C]pantothenate phosphorylation by $94% (Figure 2).
These data are consistent with all of the pantothenamides tested
here interacting with P. falciparum PanK, either as alternate
(competitive) substrates or as inhibitors of its phosphorylating
activity.
Effect of Albumax II-supplementation on the
Antiplasmodial Activity of Pantothenamides in Aged
Culture Medium
The data presented thus far are consistent with there being a
heat-labile component in Albumax-complete RPMI that antago-
nizes the activity of pantothenamides. In an attempt to identify
such a component, the activity of a selected pantothenamide
(compound 12) in aged Albumax-complete RPMI supplemented
immediately prior to the assay with various components of
Albumax-complete RPMI, was investigated. A component of the
medium that was found to antagonize the activity of pantothena-
mides was Albumax II, the lipid-rich bovine serum albumin
preparation used as a serum substitute [21]. As shown in Figure 5A
(open circles), the addition of Albumax II (0.6%, w/v) to aged
Albumax-complete medium reduced the activity of compound 12.
In the presence of the additional Albumax II, compound 12 had
little-to-no effect on parasite growth even at a concentration of
200 mM, a concentration that inhibits parasite growth completely
in aged Albumax-complete RPMI without additional Albumax.
Furthermore, the activity of pantothenol was unaffected by
supplementation with the additional Albumax II (Figure 5B),
consistent with Albumax II specifically influencing the potency of
pantothenamides. To investigate whether the attenuating effect of
Albumax II could be linked to the increased potency of
pantothenamides in Albumax-complete RPMI incubated for a
prolonged period at 37uC, we determined whether the attenuating
effect of the additional Albumax II could be alleviated by
incubating the aged medium to which additional Albumax II
had been added for a further 40 h at 37uC. The pantothenamide
was indeed more potent (.65-fold; Figure 5A, grey circles) when
tested in aged Albumax-complete RPMI supplemented with
Albumax II and aged a second time. The possibility that this
increased potency was due to further inactivation of an
independent component of the aged medium was investigated
by testing the pantothenamide in aged medium incubated for the
same total length of time as the aged Albumax-complete RPMI
supplemented with Albumax II and then incubated. Compound
12 was slightly more active in the Albumax-complete RPMI
subjected to two 40 h incubations at 37uC than in the Albumax-
complete RPMI subjected to a single 40 h incubation (Figure 5A,
closed squares). This demonstrated that a component of the
Albumax-complete RPMI had not been fully depleted/inactivated
after the initial 40 h and hence that the pantothenamide had not
reached a maximum potency in this medium after the initial 40 h
incubation. Nonetheless, the increase in potency was far less than
the increase in potency observed following incubation of the aged
medium supplemented with additional Albumax II, consistent
with the Albumax II being sensitive to heat treatment. Taken
Figure 4. Effect of pantothenate supplementation on pan-
tothenamide and pantothenol potency in fresh and aged
Albumax-complete RPMI. The bars represent the fold-increases in
the IC50 values of compound 12, compound 19 and pantothenol in
Albumax-complete RPMI following supplementation with 100 mM
pantothenate. The fold-increases in IC50 values were calculated by
dividing each IC50 value measured against P. falciparum cultured in the
presence of 100 mM pantothenate by the corresponding IC50 value
measured against P. falciparum cultured in the presence of 1 mM
pantothenate. The fold-increases in IC50 values were determined in
assays performed using Albumax-complete RPMI stored for a maximum
of 48 h at 4uC, and incubated at 37uC for a maximum of 1 h (fresh; open
bar) or Albumax-complete RPMI stored for a minimum of one week at
4uC and incubated intermittently at 37uC, or, soon after preparation,
incubated continuously at 37uC for up to 40 h (aged; closed bar). The
fold-increases in IC50 values are averaged from between two and four
independent experiments in which test compounds were tested in
Albumax-complete RPMI containing 1 mM pantothenate and Albumax-
complete RPMI supplemented with 100 mM pantothenate in parallel.
Each experiment was performed in duplicate or triplicate, and error bars
represent SEM or range/2. Pantothenol bars are shown with a broken
edge to indicate that only a lower limit on the fold-increase in IC50
could be determined. This is because less than 50% inhibition of growth
was observed at the highest pantothenol concentration tested (2 mM).
doi:10.1371/journal.pone.0054974.g004
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together, these data implicate Albumax II as the labile factor in
fresh Albumax-complete RPMI that influences the potency of
pantothenamides.
Antiplasmodial Activity in Human Serum-complete
Medium
To investigate whether the pantothenamide-attenuating prop-
erty of Albumax II was unique to this bovine serum albumin
preparation or whether the property was shared with human
serum, the activity of compound 12 in medium containing human
serum (10%, v/v), rather than Albumax II, was determined. In
human serum-complete RPMI prepared immediately prior to
growth assays (fresh human serum-complete RPMI), compound
12 had no effect on parasite growth even at a concentration of
200 mM, the highest concentration tested (Figure 6A, open circles).
In human serum-complete RPMI that had been incubated at
37uC for 40 h (aged human serum-complete RPMI), however,
compound 12 inhibited proliferation of P. falciparum with an IC50
value of 22610 mM (mean 6 range/2; n=2; Figure 6A, closed
circles). Pantothenol, on the other hand, inhibited parasite growth
with similar activity in fresh and aged human serum-complete
RPMI (Figure 6B). These data demonstrate that pantothenamide
potency is selectively enhanced in human serum-complete RPMI
following incubation of the medium at 37uC for 40 h, as it is in
Albumax-complete RPMI following incubation, consistent with
Albumax II and human serum having in common a labile
component that decreases pantothenamide potency.
Pantetheinase-mediated Pantothenamide Degradation
in vitro
The activity of pantetheinases, enzymes that catalyze the
hydrolysis of pantetheine to pantothenate and cysteamine, has
previously been detected in human serum [34]. Since pantetheine
is a secondary amide of pantothenate it more closely resembles the
pantothenamides (Figure 1) than pantothenol and other previously
reported [7,8] antiplasmodial pantothenate analogues do. In light
of this, we considered the possibility that pantothenamides in this
series are pantetheinase substrates and that Albumax II may be a
source of pantetheinase activity. To explore this hypothesis we
adapted a fluorescence-based assay used previously to measure N-
acetyl-1-D-myo-inosityl-2-amino-2-deoxy-a-D-glucopyranoside
deacetylase activity [30,31] to measure any breakdown of
compound 12 to pantothenate and isobutylamine (a primary
amine). This assay utilizes fluorescamine, a molecule which is itself
non-fluorescent, but generates a fluorescent product upon reaction
with primary amines. Using an isobutylamine standard curve,
fluorescence measurements were converted to isobutylamine
concentrations. As shown in Figure 7 (closed circles), when
compound 12 (200 mM) was incubated with recombinant human
pantetheinase (100 ng/mL), primary amine was generated, and
the concentration increased approximately linearly with time
before reaching a maximum after ,4 h. The maximum reached
corresponded to an isobutylamine concentration of ,200 mM,
consistent with all of the pantothenamide present having been
hydrolyzed. By contrast, pantothenamide hydrolysis was not
Figure 5. Effect of Albumax II supplementation on pantothenamide and pantothenol potency in aged Albumax-complete RPMI. The
concentration-response curves show the effect of increasing concentrations of compound 12 (A) and pantothenol (B) on proliferation of P.
falciparum parasites cultured (for 96 h) in Albumax-complete RPMI as measured using the SYBR Green I-based growth assay. Assays were performed
using (i) Albumax-complete RPMI incubated immediately after preparation at 37uC for 40 h (aged; closed circles); (ii) aged Albumax-complete RPMI
supplemented with additional Albumax II (0.6%, w/v) immediately prior to the assay (aged+(fresh) Albumax; open circles); (iii) aged Albumax-
complete RPMI supplemented with additional Albumax II (0.6%, w/v) and heated at 37uC for 40 h immediately prior to the assay (aged+(fresh)
Albumax+heat; grey circles); and (iv) aged Albumax-complete RPMI heated at 37uC for 40 h immediately prior to the assay (aged+heat; closed
squares). The data presented in A are averaged from three independent experiments, each performed in triplicate, and error bars represent SEM. The
data presented in B are averaged from two independent experiments, performed in duplicate or triplicate, and error bars represent range/2. For
clarity, in A, the concentration-response curves represented by the closed circles are shown with negative error bars only, and the concentration-
response curves represented by the grey circles are shown with positive error bars only. In B, the concentration-response curves represented by the
closed circles are shown with positive error bars only, and the concentration-response curves represented by the open circles are shown with
negative error bars only. Where not shown, error bars are smaller than the symbol.
doi:10.1371/journal.pone.0054974.g005
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observed when compound 12 was incubated under the same
conditions in the absence of pantetheinase (Figure 7, open circles).
Hence, these data are consistent with pantetheinase mediating the
hydrolysis of pantothenamides in addition to pantetheine. Primary
amine was also generated during incubation of compound 12 with
Albumax II (0.6%, w/v) (Figure 7, grey circles), consistent with
Albumax II (when present at a concentration equivalent to that
present in Albumax-complete medium) mediating hydrolysis of the
pantothenamide. Furthermore, incubation of Albumax II in the
absence of pantothenamide did not result in primary amine
generation (Figure 7, grey squares), which eliminated the
possibility that the amine generated resulted from degradation of
the Albumax II and not the pantothenamide. In the presence of
Albumax II, over one third of the pantothenamide present was
hydrolyzed during a 6 h incubation, and pantothenamide
hydrolysis appeared to reach completion within 24 h.
Pantetheinase-mediated Pantothenamide Degradation
under in vitro Culture Conditions
To establish whether Albumax II-mediated pantothenamide
hydrolysis could explain the reduced potency of pantothenamides
in fresh Albumax-complete RPMI, we compared the activity of
compound 12 in aged Albumax-complete RPMI with and without
recombinant human pantetheinase. As shown in Figure 8 (open
circles), 100 ng/mL recombinant human pantetheinase (when
added at the start of the assay) alleviated the antiplasmodial effect
of compound 12 in aged Albumax-complete RPMI. This result is
consistent with pantetheinase-mediated pantothenamide degrada-
tion occurring under in vitro culture conditions and, in turn,
attenuating the antiplasmodial effect of pantothenamides. Impor-
tantly, the activity of compound 12 in aged Albumax-complete
RPMI supplemented with recombinant human pantetheinase
increased after the medium was incubated at 37uC for 40 h
(Figure 8; grey circles). Moreover, the pantothenamide was more
potent in this medium than in aged Albumax-complete medium
incubated in parallel but to which the recombinant human
pantetheinase was added only after the second incubation at 37uC
(i.e. immediately prior to the assay; Figure 8; grey squares). The
latter provides evidence that the increase in pantothenamide
activity is largely due to inactivation of pantetheinase and not a
result of further inactivation of an independent component of the
medium. Taken together these data demonstrate that the
antagonizing effect of pantetheinase in parasite culture medium
can be alleviated by incubating the medium at 37uC, and are
consistent with inactivation of pantetheinase occurring during the
incubation. Hence, inactivation of Albumax II-derived pantethei-
nase during prolonged incubation at 37uC, can explain the
increase in pantothenamide potency observed when Albumax-
complete medium is incubated for a prolonged period at 37uC.
Discussion
That pantothenamides possess antibacterial activity has been
known for some time [12]. In this study we show for the first time
that pantothenamides also possess antiplasmodial activity. Addi-
tionally, we show there to be a labile serum-derived factor
common to Albumax II and human serum that specifically
antagonizes the antiplasmodial activity of pantothenamides
(Figures 5 and 6) and thereby masks their potency. We
Figure 6. Antiplasmodial effect of a pantothenamide and pantothenol in fresh and aged human serum-complete RPMI. The
concentration-response curves show the effect of increasing concentrations of compound 12 (A) and pantothenol (B) on the proliferation of P.
falciparum parasites cultured (for 96 h) in human serum-complete RPMI as measured using the SYBR Green I-based growth assay. Assays were
performed using human serum-complete RPMI prepared immediately prior to experimentation (fresh; open circles) or human serum-complete RPMI
heated at 37uC for 40 h immediately following preparation (aged; closed circles). The data obtained with parasites cultured in fresh human serum-
complete RPMI are from three independent experiments, each performed in duplicate or triplicate, and error bars represent SEM. The data obtained
with parasites cultured in aged human serum-complete RPMI are from two independent experiments, each performed in duplicate or triplicate, and
error bars represent range/2. For clarity, in B, concentration-response curves represented by the closed circles are shown with positive error bars only,
and the concentration-response curves represented by the open circles are shown with negative error bars only. Where not shown, error bars are
smaller than the symbol.
doi:10.1371/journal.pone.0054974.g006
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demonstrate this factor to be pantetheinase, an enzyme that
hydrolyzes pantetheine to form pantothenate and cysteamine.
This conclusion is based on several findings: (i) that recombinant
human pantetheinase (Vanin-1) also mediates hydrolysis of an
antiplasmodial pantothenamide (compound 12), a finding consis-
tent with earlier reports of secondary amides of pantothenate other
than pantetheine serving as pantetheinase substrates [35,36,37];
(ii) that the pantothenamide is hydrolyzed in the presence of
Albumax II (Figure 7), consistent with Albumax II, like serum,
being a source of pantetheinase activity; and (iii) that the
antiplasmodial potency of the pantothenamide is reduced in the
presence of recombinant human pantetheinase and that this
attenuating effect is alleviated by incubating the pantetheinase-
supplemented culture medium at 37uC (Figure 8). Taken together
these results provide strong evidence that in fresh medium,
pantetheinase-mediated pantothenamide degradation masks the
antiplasmodial potency of pantothenamides. Moreover, we show
that in aged culture medium, pantothenamides inhibit growth of
P. falciparum with potency unparalleled by antiplasmodial panto-
thenate analogues identified previously.
Five pantothenamides were found to inhibit growth of P.
falciparum in aged culture medium with sub-micromolar IC50
values; for one pantothenamide (compound 3), an IC50 value as
low as 20 nM was determined (Figure 2). Furthermore, the finding
that the potency of at least one pantothenamide (compound 12)
was greater in medium incubated for 80 h than in medium pre-
incubated for 40 h (the standard incubation period employed in
this study to ‘‘age’’ medium; Figure 5) is consistent with there
being residual pantetheinase activity in medium pre-incubated for
40 h, and indicates that a maximum pantothenamide potency has
not been reached in this medium. To determine the maximum
(true) potency of pantothenamides, it will be important to test the
pantothenamides under conditions where pantetheinase-mediated
degradation cannot take place. This, however, is not a trivial task.
Serum albumin is required for growth of P. falciparum [38,39] and
so to achieve strictly pantetheinase-free conditions, an albumin
preparation from which all pantetheinase activity has been
removed is needed. Whether there is pantetheinase activity
associated with preparations of human erythrocytes (required for
growth of erythrocytic-stage P. falciparum) will also need to be
Figure 7. Hydrolysis of a pantothenamide in the presence of
recombinant human pantetheinase and Albumax II. The time-
courses show the concentration of isobutylamine (a product of
compound 12 hydrolysis) detected during incubation of compound
12 with recombinant human pantetheinase (100 ng/mL; closed circles),
Albumax II (0.6%, w/v; grey circles), or an equivalent volume of water
(open circles), and during incubation of Albumax II (0.6%, w/v) in the
absence of compound 12 (grey squares). At each time-point, the
amount of primary amine was measured using a fluorescamine-based
fluorescence assay. Fluorescence measurements were converted to
isobutylamine concentrations using a standard curve generated using
isobutylamine samples of known concentration that had been
processed in the same manner as the test samples. The data are from
three or four independent experiments, each performed in duplicate,
and error bars represent SEM. For clarity, the time-courses represented
by the open circles are shown with positive error bars only, and the
time-courses represented by the grey squares are shown with negative
error bars only. Where not shown, error bars are smaller than the
symbol.
doi:10.1371/journal.pone.0054974.g007
Figure 8. Effect of pantetheinase supplementation on the
potency of a pantothenamide in aged Albumax-complete
RPMI. The concentration-response curves show the effect of increasing
concentrations of compound 12 on proliferation of P. falciparum
parasites cultured (for 96 h) in Albumax-complete RPMI as measured
using the SYBR Green I-based growth assay. Assays were performed
using (i) Albumax-complete RPMI incubated immediately after prepa-
ration at 37uC for 40 h (aged; closed circles); (ii) aged Albumax-
complete RPMI supplemented with recombinant human pantetheinase
(100 ng/mL) immediately prior to the assay (aged+pantetheinase; open
circles); (iii) aged Albumax-complete RPMI supplemented with recom-
binant human pantetheinase (100 ng/mL) and heated at 37uC for 40 h
immediately prior to the assay (aged+pantetheinase+heat; grey circles);
and (iv) aged Albumax-complete RPMI heated at 37uC for 40 h before
being supplemented with recombinant human pantetheinase (100 ng/
mL) immediately prior to the assay (aged+heat+pantetheinase; grey
squares). The data are from three independent experiments, each
performed in triplicate, and error bars represent SEM. For clarity, the
time-courses represented by the open circles are shown with negative
error bars only, and the time-courses represented by the grey squares
are shown with positive error bars only. Where not shown, error bars
are smaller than the symbol.
doi:10.1371/journal.pone.0054974.g008
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determined. Based on homology searches conducted using the
human pantetheinase sequences, the parasite genome appears
devoid of putative pantetheinase-encoding genes. This observa-
tion, and the finding that the parasite is sensitive to pantothena-
mide-mediated inhibition, suggests that the parasite is incapable of
pantetheine (and pantothenamide) hydrolysis. An alternative
strategy for determining the true potency of pantothenamides is
to test them in the presence of known pantetheinase inhibitors
[36]. However, as some pantetheinase inhibitors are also reported
to inhibit parasite growth (e.g. [40,41]) (presumably via non-
pantetheinase related mechanisms; e.g. [42]), such a strategy may
prove problematic.
The observed attenuating effect of pantothenate on the
antiplasmodial activity of pantothenamides in aged medium is
consistent with the growth inhibition resulting from inhibition of
pantothenate and/or CoA utilization, whether it be via inhibition
of (i) the uptake of pantothenate; (ii) the biosynthetic conversion of
pantothenate to CoA; or (iii) CoA-utilizing enzymes (by pantothe-
namide-derived CoA analogues). Notably, this is the first report of
compounds that inhibit growth of P. falciparum at sub-micromolar
concentrations by such a mechanism and, as such, this study
provides important further validation of pantothenate and CoA
utilization as potential antimalarial drug targets. Addition of
100 mM pantothenate was observed to alleviate growth inhibition
in the presence of pantothenamides to a much lesser extent than in
aged medium (Figure 4). To reconcile this finding, it is important
to consider that one of the products of pantothenamide hydrolysis
is pantothenate. For this reason, where pantothenamide hydrolysis
has occurred, the pantothenate concentration will have increased
from the initial 1 mM present in the medium. This will not only
attenuate the antiplasmodial effect of the pantothenamides, but
will mean that addition of 100 mM pantothenate will increase the
pantothenate concentration less than 100-fold. We did investigate
the possibility that the antiplasmodial effect observed in fresh
medium in the presence of pantothenamides was due to the
primary amines generated upon pantothenamide hydrolysis,
however, at least for the amines tested (those that should result
from hydrolysis of compounds 12, 17 and 19), little-to-no
inhibition was observed at a concentration of 200 mM (data not
shown).
We showed that all 22 pantothenamides tested inhibit P.
falciparum PanK-catalysed pantothenate phosphorylation, consis-
tent with the pantothenamides either inhibiting or serving as
alternate substrates of P. falciparum PanK. From the data presented
it is not, however, possible to discriminate between these two
possibilities. It has been shown previously that P. falciparum PanK
accepts pantothenol as a substrate for phosphorylation [43]. If
pantothenamides also serve as P. falciparum PanK substrates, it
should be investigated whether the resultant 4’-phosphopantothe-
namides are metabolized by P. falciparum CoA biosynthesis
enzymes downstream of PanK as they are by bacterial CoA
biosynthesis enzymes [17], and whether this has an effect on CoA
levels in the parasite. Inhibition of fatty acid biosynthesis (as a
result of inactivation of acyl carrier protein with pantothenamide
derived CoA analogues) has been implicated as a primary cause of
pantothenamide toxicity in E. coli [19]. As fatty acid biosynthesis is
not required during the pantothenamide-susceptible erythrocytic
stage of P. falciparum development [44,45] it is unlikely that the key
target of pantothenamides in P. falciparum is fatty acid synthesis.
For the SAR generated in this study (Figure 2) to inform future
pantothenamide design, it will be important to determine the
extent to which they reflect (i) relative efficacy against the target,
(ii) relative cell permeabilities (and/or susceptibility to efflux), (iii)
relative rates of pantetheinase-mediated hydrolysis, and (iv)
inactivation by other mechanisms including serum binding. In
light of the demonstration in this study that pantothenamides are
hydrolyzed by serum pantetheinase in vitro, it is likely that they will
also be subject to pantetheinase-mediated hydrolysis in vivo, and
thereby rendered ineffective as antiplasmodial agents in vivo.
Consistent with this, compound 12 had little-to-no effect on
parasite growth at concentrations up to 200 mM in the presence of
human serum (Figure 6A). Therefore to exploit the antiplasmodial
potency of pantothenamides it will be important to consider
strategies for circumventing pantetheinase-mediated hydrolysis
in vivo. This is also crucial for the future development of
pantothenamides as antibacterial agents, as serum stability will
be required for all but topical applications. One strategy is to
develop antiplasmodial (or antibacterial) pantothenamide ana-
logues that are resistant to degradation by pantetheinases by, for
example, using a bioisosteric replacement strategy [46,47] to
replace the key hydrolyzable amide bond. Another strategy for
circumventing pantetheinase-mediated pantothenamide hydrolysis
in vivo is to simultaneously inhibit host pantetheinase. Recently,
however, genetic studies in mice have provided evidence that a
reduction in pantetheinase activity increases susceptibility to
malaria, perhaps as a result of modulation of the inflammatory
response [48]. The design of pantetheinase-resistant pantothena-
mides may therefore be a preferable strategy for circumventing
pantetheinase-mediated degradation.
In conclusion, in this study we present, for the first time,
analogues of pantothenate that inhibit growth of P. falciparum at
sub-micromolar concentrations through inhibition of pantothenate
and/or CoA utilization, and propose the identification of
pantetheinase-resistant pantothenamide analogues as a viable
strategy for the discovery of antimalarial agents.
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